Company Number: 14924323

Analysis Date: 2025-07-19 12:23 UTC

Financial Health Assessment for FOXGLOVE LIFE SCIENCES LTD

---

1. Financial Health Score: D

Explanation:
The company shows signs of early-stage financial strain with negative net assets and working capital. Given its micro-entity status and recent incorporation, some initial investment phase losses are expected. However, the negative equity and current liabilities exceeding current assets suggest caution. The absence of revenue or profit data limits a fuller assessment, but the current snapshot indicates financial distress symptoms that require prompt attention.

---

2. Key Vital Signs

Metric	Value	Interpretation
Current Assets	£5,615	Limited cash or receivables—small liquidity buffer
Current Liabilities	£8,221	Short-term obligations exceed assets—indicates liquidity risk
Net Current Assets	-£2,606	Negative working capital—"cash flow congestion" symptom
Net Assets (Equity)	-£2,606	Negative shareholder funds—"balance sheet anemia"
Employees (average)	1	Minimal payroll burden, typical for startup/micro company
Audit Status	Exempt under Micro Entity rules	Small size with minimal filing requirements

---

3. Diagnosis

FOXGLOVE LIFE SCIENCES LTD is in its infancy, having operated just over one year since incorporation in June 2023. The financials reveal "symptoms of distress" primarily through its negative net assets and working capital deficit. This means the company currently owes more in short-term debts than it holds in assets, a classic warning sign of potential liquidity problems if not addressed swiftly.

The micro-entity filing status and the very small scale of operations (one employee) suggest the company is either still in the investment and development phase or has limited trading activity. The negative equity likely reflects initial setup costs and investments that have not yet translated into revenue or retained earnings.

The director, Dr Elizabeth Anne Coker, holds full control and voting rights, indicating centralized decision-making which can be advantageous for quick strategic shifts but also concentrates risk.

Overall, the company is not insolvent but is in a vulnerable "pre-illness" state where without sufficient cash inflows or financing, it could face solvency issues.

---

4. Recommendations

• Improve Liquidity: Secure additional working capital through equity injections from the shareholder or external financing to cover short-term liabilities and establish a healthy cash flow.
• Accelerate Revenue Generation: Prioritize commercial activities or contracts that can bring in cash inflows quickly to reverse the negative working capital trend.
• Cost Control: Maintain tight control on operational expenses given the limited asset base and current liabilities.
• Financial Monitoring: Implement monthly cash flow forecasting and financial reviews to detect early signs of distress.
• Consider Support: If cash flow issues persist, professional advice on restructuring or alternative financing may be necessary to avoid administration or liquidation risks.
• Transparency and Compliance: Continue timely filing of accounts and confirmation statements to maintain regulatory compliance and stakeholder confidence.

---